(NASDAQ: ACLX) Arcellx's forecast annual revenue growth rate of 49.4% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is forecast to beat the US market's average forecast revenue growth rate of 24.88%.
Arcellx's revenue in 2025 is $76,809,000.On average, 20 Wall Street analysts forecast ACLX's revenue for 2025 to be $2,479,526,101, with the lowest ACLX revenue forecast at $1,238,578,257, and the highest ACLX revenue forecast at $5,308,538,913. On average, 19 Wall Street analysts forecast ACLX's revenue for 2026 to be $7,957,958,980, with the lowest ACLX revenue forecast at $2,430,205,602, and the highest ACLX revenue forecast at $16,627,896,563.
In 2027, ACLX is forecast to generate $14,288,617,021 in revenue, with the lowest revenue forecast at $6,243,038,383 and the highest revenue forecast at $21,272,289,492.